Literature DB >> 30290709

Therapeutic response to glucocorticoids, anticoagulation and plasma exchange in a patient with primary antiphospholipid syndrome presenting with purpura fulminans.

M Plüß1, M Zeisberg1, G A Müller1, R Vasko1, P Korsten1.   

Abstract

We report the case of a 25-year-old female patient who presented with purpura fulminans as a manifestation of primary antiphospholipid syndrome. Purpura fulminans is considered a rare cutaneous manifestation of antiphospholipid syndrome. Most frequently, it occurs in the context of catastrophic antiphospholipid syndrome and is associated with significant morbidity and mortality, either due to loss of affected extremities or thromboembolic damage to internal organs. After insufficient efficacy of parenteral anticoagulation and oral glucocorticosteroid treatment, we escalated treatment to high-dose intravenous glucocorticosteroid and five consecutive sessions of plasma exchange with good and sustained clinical response. At follow-up six months after admission, skin manifestations had healed with scarring, and no additional thrombotic events had occurred. Plasma exchange may hold promise as a therapeutic option in refractory or severe cases of antiphospholipid syndrome-related purpura fulminans with extensive cutaneous necrosis, although evidence is limited.

Entities:  

Keywords:  Plasma exchange; antiphospholipid syndrome; purpura fulminans

Mesh:

Substances:

Year:  2018        PMID: 30290709     DOI: 10.1177/0961203318804884

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  2 in total

1.  Catastrophic Antiphospholid Syndrome - An Unusual Case Report.

Authors:  Sneha Madkaiker
Journal:  Indian J Crit Care Med       Date:  2019-06

2.  Purpura Fulminans: a Rare but Fierce Presentation of Pneumococcal Sepsis.

Authors:  Adeel Nasrullah; Anam Javed; Usman Tariq; Meilin Young; Zunera Moeen; Marvin Balaan
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.